[{"id":"9afcb6f4-d096-4d87-9778-bc395948cfef","acronym":"","url":"https://clinicaltrials.gov/study/NCT00129896","created_at":"2021-02-22T06:52:09.236Z","updated_at":"2024-07-02T16:35:54.048Z","phase":"Phase 1/2","brief_title":"Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients","source_id_and_acronym":"NCT00129896","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • doxorubicin hydrochloride • Myocet (non-pegylated liposomal doxorubicin) • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-03-06"},{"id":"89870831-32b4-4f4d-96d1-b2f5dd05299e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00297596","created_at":"2021-01-18T01:01:04.968Z","updated_at":"2024-07-02T16:36:22.343Z","phase":"Phase 2","brief_title":"Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00297596","lead_sponsor":"SCRI Development Innovations, LLC","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • oxaliplatin • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 10/01/2008","primary_completion_date":" 10/01/2008","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2021-10-28"},{"id":"db321331-a9ab-480a-ace8-ea11358ca2d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00515411","created_at":"2021-01-18T01:51:37.242Z","updated_at":"2024-07-02T16:36:52.708Z","phase":"Phase 2","brief_title":"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT00515411","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • docetaxel • 5-fluorouracil • leucovorin calcium • Neulasta (pegfilgrastim) • AP06 (trastuzumab biosimilar) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 10/23/2006","start_date":" 10/23/2006","primary_txt":" Primary completion: 10/26/2018","primary_completion_date":" 10/26/2018","study_txt":" Completion: 10/26/2018","study_completion_date":" 10/26/2018","last_update_posted":"2019-12-10"},{"id":"b5414864-2d1a-4c7e-9f7c-fde75833a8ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT00404066","created_at":"2021-02-22T06:52:14.021Z","updated_at":"2025-02-25T13:08:56.940Z","phase":"Phase 2","brief_title":"Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -\u003e Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer","source_id_and_acronym":"NCT00404066","lead_sponsor":"George Albert Fisher","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • lapatinib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Neulasta (pegfilgrastim) • AP06 (trastuzumab biosimilar) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2017-12-22"},{"id":"0004d7ee-6175-4fe2-a845-ae572abc9ea6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00021255","created_at":"2021-01-17T23:57:43.802Z","updated_at":"2024-07-02T16:37:27.625Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","source_id_and_acronym":"NCT00021255","lead_sponsor":"Sanofi","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • carboplatin • docetaxel • doxorubicin hydrochloride • cyclophosphamide • AP06 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 3222","initiation":"Initiation: 04/01/2001","start_date":" 04/01/2001","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2016-11-15"},{"id":"f412d8b7-c38d-4dfc-bd9c-450eede35f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT00493649","created_at":"2021-01-18T01:45:57.099Z","updated_at":"2024-07-02T16:37:27.781Z","phase":"Phase 2","brief_title":"Adj TC + Herceptin Early Stage Breast Cancer","source_id_and_acronym":"NCT00493649","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • TOP2A","pipe":" | ","alterations":" TOP2A amplification","tags":["HER-2 • TOP2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TOP2A amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • cyclophosphamide • AP06 (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 493","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2016-11-03"},{"id":"ae2fe60f-b070-447a-b2c4-028f7bd0f6b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01042925","created_at":"2021-01-18T04:05:47.746Z","updated_at":"2024-07-02T16:37:31.530Z","phase":"Phase 1/2","brief_title":"Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen","source_id_and_acronym":"NCT01042925","lead_sponsor":"Sanofi","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • pilaralisib (SAR245408) • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 12/01/2012","primary_completion_date":" 12/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2016-06-03"},{"id":"6ff438ff-60db-42d8-ade3-dfe9cec1186a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00387907","created_at":"2021-01-18T01:21:00.489Z","updated_at":"2024-07-02T16:37:32.371Z","phase":"Phase 2","brief_title":"Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00387907","lead_sponsor":"Sanofi","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • AP06 (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 03/01/2008","primary_completion_date":" 03/01/2008","study_txt":" Completion: 03/01/2008","study_completion_date":" 03/01/2008","last_update_posted":"2016-05-05"}]